Clinical Trial Update: Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg [Phase 2]

View source ↗

Summary

Phase 2 trial updating the efficacy and safety of lanreotide Autogel in pancreatic and midgut neuroendocrine tumors after progression on prior lanreotide therap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Midgut Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Lanreotide Autogel (lanreotide)

Snippet

Sponsor: Ipsen | Conditions: Pancreatic Tumours, Midgut Neuroendocrine Tumours | Phase 2 | Status: COMPLETED | Results posted: 2020-12-30